These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 34119742)

  • 21.
    Bensch F; van der Veen EL; Lub-de Hooge MN; Jorritsma-Smit A; Boellaard R; Kok IC; Oosting SF; Schröder CP; Hiltermann TJN; van der Wekken AJ; Groen HJM; Kwee TC; Elias SG; Gietema JA; Bohorquez SS; de Crespigny A; Williams SP; Mancao C; Brouwers AH; Fine BM; de Vries EGE
    Nat Med; 2018 Dec; 24(12):1852-1858. PubMed ID: 30478423
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Advancing
    Wuensche TE; Stergiou N; Mes I; Verlaan M; Schreurs M; Kooijman EJM; Janssen B; Windhorst AD; Jensen A; Asuni AA; Bang-Andersen B; Beaino W; Dongen GAMS; Vugts DJ
    Theranostics; 2022; 12(16):7067-7079. PubMed ID: 36276653
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Visualizing Galectin-3 Binding Protein Expression with ImmunoPET.
    Keinänen O; Sarrett SM; Delaney S; Rodriguez C; Dayts EJ; Capone E; Sauniere F; Ippoliti R; Sala G; Iacobelli S; Zeglis BM
    Mol Pharm; 2023 Jun; 20(6):3241-3248. PubMed ID: 37191353
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Development of Novel ImmunoPET Tracers to Image Human PD-1 Checkpoint Expression on Tumor-Infiltrating Lymphocytes in a Humanized Mouse Model.
    Natarajan A; Mayer AT; Reeves RE; Nagamine CM; Gambhir SS
    Mol Imaging Biol; 2017 Dec; 19(6):903-914. PubMed ID: 28247187
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Radiolabelling and preclinical characterization of
    Burvenich IJG; Goh YW; Guo N; Gan HK; Rigopoulos A; Cao D; Liu Z; Ackermann U; Wichmann CW; McDonald AF; Huynh N; O'Keefe GJ; Gong SJ; Scott FE; Li L; Geng W; Zutshi A; Lan Y; Scott AM
    Eur J Nucl Med Mol Imaging; 2021 Sep; 48(10):3075-3088. PubMed ID: 33608805
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Radiolabelling and preclinical characterisation of [
    Cao Z; Wichmann CW; Burvenich IJG; Osellame LD; Guo N; Rigopoulos A; O'Keefe GJ; Scott FE; Lorensuhewa N; Lynch KP; Scott AM
    Eur J Nucl Med Mol Imaging; 2024 Sep; 51(11):3202-3214. PubMed ID: 38730087
    [TBL] [Abstract][Full Text] [Related]  

  • 27. An Analysis of Isoclonal Antibody Formats Suggests a Role for Measuring PD-L1 with Low Molecular Weight PET Radiotracers.
    Wei J; Wang YH; Lee CY; Truillet C; Oh DY; Xu Y; Ruggero D; Flavell RR; VanBrocklin HF; Seo Y; Craik CS; Fong L; Wang CI; Evans MJ
    Mol Imaging Biol; 2020 Dec; 22(6):1553-1561. PubMed ID: 32813112
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Preclinical development of novel PD-L1 tracers and first-in-human study of [
    Zhang Y; Cao M; Wu Y; Malih S; Xu D; Yang E; Younis MH; Lin W; Zhao H; Wang C; Liu Q; Engle JW; Rasaee MJ; Guan Y; Huang G; Liu J; Cai W; Xie F; Wei W
    J Immunother Cancer; 2024 Apr; 12(4):. PubMed ID: 38580333
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Development of novel peptide-based radiotracers for detecting PD-L1 expression and guiding cancer immunotherapy.
    Zhu S; Liang B; Zhou Y; Chen Y; Fu J; Qiu L; Lin J
    Eur J Nucl Med Mol Imaging; 2024 Feb; 51(3):625-640. PubMed ID: 37878029
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Evaluation and selection of a lead diabody for interferon-γ PET imaging.
    Rezazadeh F; Ramos N; Saliganan AD; Barr S; Peraino N; Schomburg F; Rancour D; Viola NT
    Nucl Med Biol; 2022; 114-115():162-167. PubMed ID: 35753939
    [TBL] [Abstract][Full Text] [Related]  

  • 31. PD-L1 Detection in Tumors Using [(64)Cu]Atezolizumab with PET.
    Lesniak WG; Chatterjee S; Gabrielson M; Lisok A; Wharram B; Pomper MG; Nimmagadda S
    Bioconjug Chem; 2016 Sep; 27(9):2103-10. PubMed ID: 27458027
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Construction and preclinical evaluation of a zirconium-89 labelled monoclonal antibody targeting PD-L2 in lung cancer.
    Yao Y; Ren Y; Hou X; Zhu J; Ma X; Liu S; Liu T; Zhang Q; Ma X; Yang Z; Zhu H; Li N
    Biomed Pharmacother; 2023 Dec; 168():115602. PubMed ID: 37852097
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Imaging PD-L1 Expression with ImmunoPET.
    Truillet C; Oh HLJ; Yeo SP; Lee CY; Huynh LT; Wei J; Parker MFL; Blakely C; Sevillano N; Wang YH; Shen YS; Olivas V; Jami KM; Moroz A; Jego B; Jaumain E; Fong L; Craik CS; Chang AJ; Bivona TG; Wang CI; Evans MJ
    Bioconjug Chem; 2018 Jan; 29(1):96-103. PubMed ID: 29125731
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Imaging of Programmed Cell Death Ligand 1: Impact of Protein Concentration on Distribution of Anti-PD-L1 SPECT Agents in an Immunocompetent Murine Model of Melanoma.
    Nedrow JR; Josefsson A; Park S; Ranka S; Roy S; Sgouros G
    J Nucl Med; 2017 Oct; 58(10):1560-1566. PubMed ID: 28522738
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A Preclinical Assessment of
    Moroz A; Lee CY; Wang YH; Hsiao JC; Sevillano N; Truillet C; Craik CS; Fong L; Wang CI; Evans MJ
    Bioconjug Chem; 2018 Oct; 29(10):3476-3482. PubMed ID: 30227708
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Positron-Emission Tomography of HER2-Positive Breast Cancer Xenografts in Mice with
    Al-Saden N; Lam K; Chan C; Reilly RM
    Mol Pharm; 2018 Aug; 15(8):3383-3393. PubMed ID: 29957952
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Noninvasive Imaging and Quantification of Radiotherapy-Induced PD-L1 Upregulation with
    Ehlerding EB; Lee HJ; Barnhart TE; Jiang D; Kang L; McNeel DG; Engle JW; Cai W
    Bioconjug Chem; 2019 May; 30(5):1434-1441. PubMed ID: 30973703
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Immuno-PET Imaging of CD30-Positive Lymphoma Using 89Zr-Desferrioxamine-Labeled CD30-Specific AC-10 Antibody.
    Rylova SN; Del Pozzo L; Klingeberg C; Tönnesmann R; Illert AL; Meyer PT; Maecke HR; Holland JP
    J Nucl Med; 2016 Jan; 57(1):96-102. PubMed ID: 26514172
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Comparison of the octadentate bifunctional chelator DFO*-pPhe-NCS and the clinically used hexadentate bifunctional chelator DFO-pPhe-NCS for
    Vugts DJ; Klaver C; Sewing C; Poot AJ; Adamzek K; Huegli S; Mari C; Visser GWM; Valverde IE; Gasser G; Mindt TL; van Dongen GAMS
    Eur J Nucl Med Mol Imaging; 2017 Feb; 44(2):286-295. PubMed ID: 27573793
    [TBL] [Abstract][Full Text] [Related]  

  • 40. A Pretargeted Imaging Strategy for Immune Checkpoint Ligand PD-L1 Expression in Tumor Based on Bioorthogonal Diels-Alder Click Chemistry.
    Qiu L; Tan H; Lin Q; Si Z; Mao W; Wang T; Fu Z; Cheng D; Shi H
    Mol Imaging Biol; 2020 Aug; 22(4):842-853. PubMed ID: 31741201
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.